Gordon Research Conferences
PI_Conferences PI_Conferences_Past
Conference Program
 
Tuberculosis Drug Development
Targets, Technologies and Trials
(This meeting is currently known as "Tuberculosis Drug Discovery & Development")
August 16-21, 2009
Magdalen College
Oxford, United Kingdom

The 2009 Gordon Conference on Tuberculosis Drug Development will cover the range of activities involved in producing new antibiotics. The conference will feature discussion of target and compound discovery, new potential antituberculous compounds in development, clinical trial design and early trial results and alternative approaches to tuberculosis treatment. We invite researchers interested in all of these aspects of drug development and welcome participants from academia, industry, government and non-governmental organizations. In particular, we invite trainees and scientists from developing countries to apply. All participants are asked to submit abstracts of their work for presentation as posters. Some abstracts will be chosen for oral presentations. The conference provides the opportunity to interact with colleagues in an informal and intimate atmosphere and is designed to promote the most possible discussion. The meeting has been oversubscribed in the past - please apply early!


Contributors
AstraZeneca
Cell Press
Global Alliance for TB Drug Development
National Institutes of Health
Tibotec BVBA

SUNDAY
4:00 pm - 8:00 pmArrival and Check-in (Office Closed 6:00 pm - 7:00 pm)
5:30 pmWelcome Reception on the Cloisters Lawn
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pm The Global Challenge of Tuberculosis
Discussion Leader: Bala Subramanian (AstraZeneca)
7:40 pm - 8:20 pm Gary Maartens (University of Cape Town)
"A Tale of Two Epidemics: HIV and TB"
8:20 pm - 8:35 pm Discussion
8:35 pm - 9:15 pmZarir Udwadia (Hinduja Hospital)
"Tackling MDR and XDR TB in resource limited settings: the Indian scenario"
9:15 pm - 9:30 pm Discussion
MONDAY
8:00 am - 9:00 amBreakfast
9:00 am - 12:30 pm Potential New Targets for Treating Tuberculosis
Discussion Leader: Valerie Mizrahi (University of the Witwatersrand)
9:00 am - 9:35 amChristopher Sassetti (University of Massachusetts Medical School)
"Metabolic adaptations required for infection and dormancy"
9:35 am - 9:45 am Discussion
9:45 am - 9:55 am Juliane Ollinger (IDRI)
"Signal peptidase I as a target for the development of new treatments against Mycobacterium tuberculosis"
9:55 am - 10:00 am Discussion
10:00 am Coffee Break / Group Photo
10:30 am - 11:00 amGiovanna Riccardi (University of Pavia)
"Rv3790 from Mycobacterium tuberculosis is the magic target"
11:00 am - 11:10 am Discussion
11:10 am - 11:40 am Deborah Hung (Broad Institute)
11:40 am - 11:55 am Discussion
11:55 am - 12:05 pm Lisa Prach (University of California, Berkeley)
"Structure and biosynthesis of novel diterpenes in Mycobacterium tuberculosis"
12:05 pm - 12:10 pm Discussion
12:10 pm - 12:20 pmMarie Lavollay (University of Paris V)
"L,D-Transpeptidases of Mycobacterium tuberculosis : Novel cell-wall targets for the eradication of non-replicative forms of Mycobacterium tuberculosis?"
12:20 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session I
6:00 pmDinner
7:30 pm - 9:30 pm New chemical entities I
Discussion Leader: José Garcia-Bustos (GlaxoSmithKline)
7:30 pm - 8:00 pmThomas Dick (Novartis Institute for Tropical Disease)
"Hits from aerobic and anaerobic whole cell and respiratory vesicle screens"
8:00 pm - 8:10 pm Discussion
8:10 pm - 8:35 pmVadim Makarov (AN Bakh Institute of Biochemistry)
"1,4-Benzothiazinones - new class of antituberculosis compounds"
8:35 pm - 8:45 pm Discussion
8:45 pm - 9:15 pmSunita DeSousa (AstraZeneca)
"Twists and a tale - DNA gyrase for TB drug discovery"
9:15 pm - 9:30 pm Discussion
TUESDAY
8:00 am - 9:00 amBreakfast
9:00 am - 12:30 pm Screening for new antibiotics
Discussion Leader: Stewart Cole (EFPL)
9:00 am - 9:35 amPriscille Brodin (Institut Pasteur Korea)
"High content screening on the Mycobacterium tuberculosis infected macrophage"
9:35 am - 9:45 am Discussion
9:45 am - 9:55 am Thulassi Warrier (Max Planck Institute, Berlin)
"Identification and Characterization of Small Molecule Inhibitors of Mycobacterium tuberculosis Antigen 85C"
9:55 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 11:00 amDerek Tan (Memorial Sloan Kettering)
"Natural product-based libraries for chemical biology and drug discovery"
11:00 am - 11:10 am Discussion
11:10 am - 11:40 amRobert Reynolds (Southern Research Institute)
"High throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv"
11:40 am - 11:50 am Discussion
11:50 am - 12:15 pm Randy Basaraba (Colorado State University)
"The formation and survival of microbial communities of Mycobacterium tuberculosis"
12:15 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session I
6:00 pmDinner
7:30 pm - 9:30 pm Model systems
Discussion Leader: Ken Duncan (Bill and Melinda Gates Foundation)
7:30 pm - 8:00 pmTawanda Gumbo (University of Texas, Southwestern)
"From bactericidal to sterilizing effect: Evidence that in vitro PK/PD model systems correlate with clinical outcomes"
8:00 pm - 8:10 pm Discussion
8:10 pm - 8:35 pmAjit Lalvani (Imperial College)
"Biomarkers of treatment response to accelerate clinical trials of new drugs"
8:35 pm - 8:45 pm Discussion
8:45 pm - 9:15 pmJoAnne Flynn (University of Pittsburgh)
"Predicting drug cure at the single lesion level: the use of imaging in TB drug studies"
9:15 pm - 9:30 pm Discussion
WEDNESDAY
8:00 am - 9:00 amBreakfast
9:00 am - 12:30 pm New chemical entities II
Discussion Leader: Véronique Dartois (Novartis Institute for Tropical Disease)
9:00 am - 9:35 amDavid Barros (GlaxoSmithKline)
"Novel Mtb DNA gyrase inhibitors"
9:35 am - 9:45 am Discussion
9:45 am - 9:55 am Sylvia Luckner (Rudolph Virchow Center)
"Mycobacterial Cell Wall Biosynthesis and Inhibition of KasA by Thiolactomycin"
9:55 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 11:00 amJean-Emmanuel Hugonnet (Albert Einstein College of Medicine)
"Tuberculosis: Finding and Achilles heel"
11:00 am - 11:10 am Discussion
11:10 am - 11:40 am Geoffrey Coxon (University of Strathclyde)
"The identification of 2-aminothiazole-4-carboxylates active against Mycobacterium tuberculosis"
11:40 am - 11:50 am Discussion
11:50 am - 12:15 pm Eric Nuermberger (Johns Hopkins)
"Pre-clnical results with PNU-100480 and further observations on testing new drugs in mice"
12:15 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session II
6:00 pmDinner
7:00 pm - 7:30 pmBusiness Meeting
(Nominations for the next Vice Chair; Fill out Conference Evaluation Forms; Discuss future Site & Scheduling preferences; Election of the next Vice Chair)
7:30 pm - 9:30 pm Alternative approaches to tuberculosis therapy
Discussion Leader: Jim Sacchettini (Texas A&M)
7:30 pm - 8:10 pmJacques Neefjes (The Netherlands Cancer Institute)
"Development of the host kinase and phosphatase inhibitors to control bacterial infections. And how they work"
8:10 pm - 8:30 pm Discussion
8:30 pm - 9:10 pm Gilla Kaplan (Public Health Research Institute)
"The Effect of Modulation of Innate Immunity on Tuberculosis Pathogenesis and Response to Antibiotic Treatment"
9:10 pm - 9:30 pm Discussion
THURSDAY
8:00 am - 9:00 amBreakfast
9:00 am - 12:30 pm Early clinical trials
Discussion Leader: Ann Ginsberg (Global Alliance for TB Drug Development)
9:00 am - 9:45 amClifton Barry (NIH)
"in vivo imaging of tuberculosis and the response to chemotherapy: PET as a surrogate marker for drug efficacy"
9:45 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 11:00 amNgozi Erondu (Global Alliance for TB Drug Development)
"Update on the clinical development of PA-824"
11:00 am - 11:10 am Discussion
11:10 am - 11:40 am Andreas Diacon (University of Stellenbosch)
"Perspective on TMC207"
11:40 am - 11:50 am Discussion
11:50 am - 12:15 pm Alain Baulard (Pasteur Institut, Lille)
"EthR inhibitors boost antituberculous activity of ethionamide"
12:15 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 5:30 pmPoster Session II
5:30 pmReception on the Cloisters Lawn
6:00 pmDinner
7:30 pm - 9:30 pm How should new drugs be tested?
Discussion Leader: Eric Rubin (Harvard)
7:30 pm - 7:55 pmLawrence Geiter (Otsuka Pharmaceuticals)
"Practical issues in the implementation of tuberculosis clinical trials: lessons learned and challenges faced in the implementation of a phase IIB trial"
7:55 pm - 8:05 pm Discussion
8:05 pm - 8:30 pmMel Spigelman (Global Alliance for TB Drug Development)
"Innovative approaches to the clinical development of new anti-tuberculosis agents"
8:30 pm - 8:45 pm Discussion
8:45 pm - 9:15 pmChris Lipinski (Melior Discovery)
"August 21, 2009: Where is TB drug discovery today?"
9:15 pm - 9:30 pm Discussion
FRIDAY
8:00 am - 9:00 amBreakfast
9:00 amDeparture

Funding for this conference was made possible [in part] by 1R13AI082702-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


 
© 2014 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter